158 related articles for article (PubMed ID: 36218218)
1. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
Sim B; Ng JY; Teh BW; Talaulikar D
Leuk Lymphoma; 2023 Jan; 64(1):18-29. PubMed ID: 36218218
[TBL] [Abstract][Full Text] [Related]
2. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
[TBL] [Abstract][Full Text] [Related]
3. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
[TBL] [Abstract][Full Text] [Related]
4. Infections in secondary immunodeficiency patients treated with Privigen
Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
[TBL] [Abstract][Full Text] [Related]
5. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.
Shah N; Mustafa SS; Vinh DC
Crit Rev Oncol Hematol; 2023 Jan; 181():103896. PubMed ID: 36528276
[TBL] [Abstract][Full Text] [Related]
6. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
7. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies.
Jolles S; Smith BD; Vinh DC; Mallick R; Espinoza G; DeKoven M; Divino V
Leuk Lymphoma; 2022 Jan; 63(1):64-73. PubMed ID: 34702119
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
Patel V; Cowan J
Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
[TBL] [Abstract][Full Text] [Related]
10. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
[TBL] [Abstract][Full Text] [Related]
11. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Hematology; 2019 Dec; 24(1):173-182. PubMed ID: 30458690
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
[TBL] [Abstract][Full Text] [Related]
13. Access and use of immunoglobulins in supportive cancer care: A thematic analysis of a systematic review data set.
Counihan M; Cervenakova L; Misztela D; Van Baelen M; D Naughton B
J Med Access; 2024; 8():27550834241236596. PubMed ID: 38559466
[TBL] [Abstract][Full Text] [Related]
14. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China.
Ye C; Liu J; Song X; Zheng S; Liu J
Medicine (Baltimore); 2021 Jan; 100(3):e23935. PubMed ID: 33545966
[TBL] [Abstract][Full Text] [Related]
15. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
[TBL] [Abstract][Full Text] [Related]
16. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
[TBL] [Abstract][Full Text] [Related]
17. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
Ohmoto A; Fuji S; Shultes KC; Savani BN; Einsele H
Bone Marrow Transplant; 2022 Jun; 57(6):874-880. PubMed ID: 35440805
[TBL] [Abstract][Full Text] [Related]
18. Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives.
Ar MC; El Fakih R; Gabbassova S; Alhuraiji A; Nasr F; Alsaeed A; Sayinalp N; Marashi M
Leuk Res; 2023 Oct; 133():107365. PubMed ID: 37643508
[TBL] [Abstract][Full Text] [Related]
19. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.
Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T
Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.
Link H; Kerkmann M; Holtmann L; ;
Support Care Cancer; 2022 Jun; 30(6):5187-5200. PubMed ID: 35257229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
